MedTrace Logo

Study to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Patients With Rheumatoid Arthritis

NCT02780323 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2020-02-05

No results posted yet for this study

Summary

This Phase IV clinical study is to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Rheumatoid Arthritis Patients

Conditions

Interventions

DRUG

CELBESTA®

1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks

DRUG

CELEBREX®

1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks

DRUG

CELEBREX® placebo

1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks

DRUG

CELBESTA® placebo

1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks

Sponsors & Collaborators

  • Dong-A ST Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Seung-jae Hong, MD,PhD · Kyung Hee University Hospital

  • Sungsoo Kim, MD,PhD · Gangneung Asan Hospital

  • Sangil Lee, MD,PhD · Gyeongsang National Hospital

  • Changnam Son, MD,PhD · Keimyung University Dongsan Medical Center

  • Yeong Ho Seo, MD,PhD · Korea University

  • Geun-Tae Kim, MD,PhD · Kosin University Gospel Hospital

  • Jin-Wuk Hur, MD,PhD · Seoul Eulji Hospital

  • Hyun-Sook Kim, MD,PhD · Soonchunhyang University Hospital

  • Myeong Soo Lee, MD,PhD · Wonkwang University Hospital

  • Yun Sung Kim, MD,PhD · Chosun University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-02
Primary Completion
2017-12-26
Completion
2017-12-26

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02780323 on ClinicalTrials.gov